• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

    2/7/24 8:42:56 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MRNA alert in real time by email
    SC 13G/A 1 d752423dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934*

    (Amendment No. 5)

     

     

    Moderna, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    60770K 107

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 60770K107

     

     1.   

     Names of Reporting Person

     

     Stéphane Bancel

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☐  (b) ☒

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     France

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.   

     Sole Voting Power

     

     30,384,866 (1)

       6.  

     Shared Voting Power

     

     0

       7.  

     Sole Dispositive Power

     

     30,384,866 (1)

       8.  

     Shared Dispositive Power

     

     0

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     30,384,866 (1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     7.8% (2)

    12.  

     Type of Reporting Person (See Instructions)

     

     IN

     

    (1)

    Consists of (i) 5,429,839 shares of Common Stock held directly by Mr. Bancel, (ii) 9,339,775 shares issuable to Mr. Bancel upon exercise of share options exercisable within 60 days after December 31, 2023, (iii) 6,564,880 shares of Common Stock held by OCHA LLC, and (iv) 9,050,372 shares of Common Stock held by Boston Biotech Ventures, LLC.

    (2)

    Percentage ownership is calculated based on (i) 381,794,720 shares of Common Stock outstanding as of December 31, 2023 and (ii) 9,339,775 shares of Common Stock underlying the share options held by Mr. Bancel that are exercisable within 60 days of December 31, 2023 which are deemed outstanding pursuant to SEC Rule 13-3(d)(1)(i).

    (3)

    Percentage ownership is calculated based on 381,794,720 shares of Common Stock outstanding as of December 31, 2023.


    CUSIP No. 60770K107

     

     1.   

     Names of Reporting Person

     

     OCHA LLC

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☐  (b) ☒

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.   

     Sole Voting Power

     

     6,564,880

       6.  

     Shared Voting Power

     

     0

       7.  

     Sole Dispositive Power

     

     6,564,880

       8.  

     Shared Dispositive Power

     

     0

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     6,564,880

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     1.7% (3)

    12.  

     Type of Reporting Person (See Instructions)

     

     OO


    CUSIP No. 60770K107

     

     1.   

     Names of Reporting Person

     

     Boston Biotech Ventures, LLC

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     

     (a) ☐  (b) ☒

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.   

     Sole Voting Power

     

     9,050,372

       6.  

     Shared Voting Power

     

     0

       7.  

     Sole Dispositive Power

     

     9,050,372

       8.  

     Shared Dispositive Power

     

     0

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     9,050,372

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     2.4% (3)

    12.  

     Type of Reporting Person (See Instructions)

     

     OO


    Item 1.

     

      (a)

    Name of Issuer

    Moderna, Inc. (the “Issuer”)

     

      (b)

    Address of Issuer’s Principal Executive Offices

    200 Technology Square

    Cambridge, MA 02139

     

    Item 2.

     

      (a)

    Name of Person Filing

    Stéphane Bancel

    OCHA LLC

    Boston Biotech Ventures, LLC

     

      (b)

    Address of Principal Business Office or, if none, Residence

    c/o Moderna, Inc.

    200 Technology Square

    Cambridge, MA 02139

     

      (c)

    Citizenship

    Stéphane Bancel is a citizen of France. Each of OCHA LLC and Boston Biotech Ventures, LLC is a Delaware limited liability company.

     

      (d)

    Title of Class of Securities

    Common Stock, par value $0.0001 per share

     

      (e)

    CUSIP Number

    60770K107

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

         (a)    ☐    Broker or dealer registered under Section 15 of the Act;
      (b)    ☐    Bank as defined in Section 3(a)(6) of the Act;
      (c)    ☐    Insurance company as defined in Section 3(a)(19) of the Act;
      (d)    ☐    Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e)    ☐    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f)    ☐    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
      (g)    ☐    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
      (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
      (j)    ☐    A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
      (k)    ☐    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:


    Item 4.

    Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) and (b) Amount beneficially owned:

     

      (i)

    Mr. Bancel directly owns 5,429,839 shares of Common Stock and 9,339,775 shares issuable to Mr. Bancel upon exercise of share options exercisable within 60 days after December 31, 2023. In addition, Mr. Bancel may be deemed to have voting and dispositive power over (i) 6,564,880 shares of Common Stock directly owned by OCHA LLC, of which Mr. Bancel is the majority unit holder and sole managing member, and (ii) 9,050,372 shares of Common Stock directly owned by Boston Biotech Ventures, LLC, of which Mr. Bancel is the majority unit holder and the sole managing member. Mr. Bancel disclaims Section 13(d) beneficial ownership over all shares held by OCHA LLC and Boston Biotech Ventures, LLC, and this report shall not be deemed an admission that Mr. Bancel is the beneficial owner of such shares for Section 13(d) or any other purpose. The aggregate of 30,384,866 shares of Common Stock with respect to which Mr. Bancel may be deemed to have voting and dispositive power represents approximately 7.8% of the outstanding shares of Common Stock.

     

      (ii)

    OCHA LLC directly owns 6,564,880 shares of Common Stock. The percent of class was calculated based on 381,794,720 shares of Common Stock outstanding as of December 31, 2023.

     

      (iii)

    Boston Biotech Ventures, LLC directly owns 9,050,372 shares of Common Stock. The percent of class was calculated based on 381,794,720 shares of Common Stock outstanding as of December 31, 2023.

    (c) Number of shares as to which such person has:

     

         Number of Shares of Common Stock  
    Reporting Person    (i)      (ii)      (iii)      (iv)  

    Stéphane Bancel

         30,384,866 *       0        30,384,866 *       0  

    OCHA LLC

         6,564,880        0        6,564,880        0  

    Boston Biotech Ventures, LLC

         9,050,372        0        9,050,372        0  

     

    (i)

    Sole power to vote or direct the vote

     

    (ii)

    Shared power to vote or to direct the vote

     

    (iii)

    Sole power to dispose or to direct the disposition of

     

    (iv)

    Shared power to dispose or to direct the disposition of

     

    *

    See Item 4(a) and (b) above.

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    Not applicable.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not applicable.


    Item 8.

    Identification and Classification of Members of the Group

    The reporting persons disclaim the existence of a “group” as that term is used in Rule 13d-5(b) of the Securities Exchange Act of 1934, as amended.

     

    Item 9.

    Notice of Dissolution of Group

    Not applicable.

     

    Item 10.

    Certification

    Not applicable.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 7, 2024     STÉPHANE BANCEL
       

    /s/ Stéphane Bancel

        OCHA LLC
        By:   /s/ Stéphane Bancel
        Name:   Stéphane Bancel
        Title:   Managing Member
        BOSTON BIOTECH VENTURES, LLC
        By:   /s/ Stéphane Bancel
        Name:   Stéphane Bancel
        Title:   Managing Member


    Joint Filing Agreement

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

     

    Date: February 7, 2024     STÉPHANE BANCEL
       

    /s/ Stéphane Bancel

        OCHA LLC
        By:   /s/ Stéphane Bancel
        Name:   Stéphane Bancel
        Title:   Managing Member
        BOSTON BIOTECH VENTURES, LLC
        By:   /s/ Stéphane Bancel
        Name:   Stéphane Bancel
        Title:   Managing Member
    Get the next $MRNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRNA

    DatePrice TargetRatingAnalyst
    3/13/2025$40.00Neutral
    Citigroup
    2/18/2025$111.00 → $45.00Overweight → Equal Weight
    Barclays
    1/29/2025$99.00 → $51.00Buy → Neutral
    Goldman
    12/18/2024Buy → Hold
    Argus
    12/10/2024$41.00Underperform
    BofA Securities
    11/19/2024$42.00Hold
    Berenberg
    11/18/2024$58.00Hold → Buy
    HSBC Securities
    11/15/2024$40.00Underperform
    Wolfe Research
    More analyst ratings

    $MRNA
    Financials

    Live finance-specific insights

    See more
    • Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates

      Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0 to $3.5 billionInitiated dosing in two pivotal Phase 3 trials to assess efficacy of investigational mRNA vaccines against norovirus and influenzaAnnounces expansion of its Executive Committee CAMBRIDGE, MA / ACCESSWIRE / November 7, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the third quarter of 2024."During the third quarter, we focused on execution with the launch of our updated COVID-19 and RSV vaccines in markets across the globe. I

      11/7/24 6:30:00 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024

      CAMBRIDGE, MA / ACCESSWIRE / October 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 7, 2024 to report its third quarter 2024 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the adv

      10/17/24 7:05:00 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates

      Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33)Updates 2024 financial framework and revises expectations for product sales to $3.0 to $3.5 billionReceived U.S. FDA approval for RSV vaccine, mRESVIA, and began shipping in July; received EMA positive opinion in JuneAnnounced positive Phase 3 data for combination vaccine against influenza and COVID-19Announced positive Phase 3 data for next-generation COVID-19 vaccine CAMBRIDGE, MA / ACCESSWIRE / August 1, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2024."During the second quarter, we marked the approval of our

      8/1/24 6:30:00 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MRNA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

      For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

      11/30/20 5:12:14 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Moderna with a new price target

      Citigroup initiated coverage of Moderna with a rating of Neutral and set a new price target of $40.00

      3/13/25 8:15:14 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Moderna downgraded by Barclays with a new price target

      Barclays downgraded Moderna from Overweight to Equal Weight and set a new price target of $45.00 from $111.00 previously

      2/18/25 7:11:52 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Moderna downgraded by Goldman with a new price target

      Goldman downgraded Moderna from Buy to Neutral and set a new price target of $51.00 from $99.00 previously

      1/29/25 7:08:27 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MRNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      3/4/25 4:27:16 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      3/4/25 4:24:36 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MRNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics

      CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Quotient Therapeutics, a company pioneering somatic genomics, today announced that Rahul Kakkar, M.D., will join Flagship Pioneering as CEO-Partner and Quotient Therapeutics as Chief Executive Officer. Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience founding and building biotechnology companies and practicing medicine. Previously, he served as President and CEO of Tome Biosciences, a genome engineering biotec

      4/29/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health

      Owen joins to lead new phase of growth for the medical device company in clinical trial, diagnostic, and reference laboratory applications CAMBRIDGE, Mass., Feb. 19, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and YourBio Health, a pioneer in remote blood collection technology, today announced the appointment of Paul Owen as Chief Executive Officer of YourBio Health and CEO-Partner of Flagship Pioneering. Owen joins YourBio Health and Flagship after a corporate leadership and strategic planning career spanning more than 35 years. He was most r

      2/19/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies

      CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin

      11/20/24 8:00:00 AM ET
      $FHTX
      $MRNA
      $OMGA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $MRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Tallett Elizabeth E

      4 - Moderna, Inc. (0001682852) (Issuer)

      5/1/25 4:36:15 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Sagan Paul

      4 - Moderna, Inc. (0001682852) (Issuer)

      5/1/25 4:35:11 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Rubenstein David M. converted options into 677 shares (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      5/1/25 4:34:05 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MRNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics

      CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Quotient Therapeutics, a company pioneering somatic genomics, today announced that Rahul Kakkar, M.D., will join Flagship Pioneering as CEO-Partner and Quotient Therapeutics as Chief Executive Officer. Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience founding and building biotechnology companies and practicing medicine. Previously, he served as President and CEO of Tome Biosciences, a genome engineering biotec

      4/29/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Flagship Pioneering Unveils Etiome to Pioneer Preemptive Healthcare

      Etiome's Temporal Biodynamics™ AI-powered platform is the first end-to-end solution to detect disease and preempt progression before it becomes too late Company emerges following four years of platform development and an initial commitment of $50 million from Flagship Pioneering CAMBRIDGE, Mass., April 24, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Etiome, a company redefining how we detect and preempt disease progression. Etiome's Temporal Biodynamics™ platform is the first end-to-end technology to characterize disease with increased resolution over time and accelerate the development of preemptive medicines that promise better health outcom

      4/24/25 6:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders

      Believes Company's Misguided Acquisition Strategy is Destroying Value and Preventing Dynavax from Maximizing the Opportunities of Heplisav for Shareholders and Patients In Deep Track's View, Properly Focusing on Heplisav Could Result in More than $1 Billion in Cash Generation by 2030 – More than Dynavax's Current Enterprise Value Sees Shareholder Representation on Board as Necessary to Restore Investor Confidence in Dynavax and Prevent Strategic Blunders Urges Shareholders to Vote FOR Deep Track's Four Highly Qualified Director Nominees Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDA

      4/21/25 4:05:00 PM ET
      $DVAX
      $MRNA
      $SNY
      $TARS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $MRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

      SC 13G/A - Moderna, Inc. (0001682852) (Subject)

      4/10/24 2:03:52 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

      SC 13G/A - Moderna, Inc. (0001682852) (Subject)

      2/7/24 8:42:56 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

      SC 13G/A - Moderna, Inc. (0001682852) (Subject)

      1/29/24 3:26:24 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MRNA
    SEC Filings

    See more
    • Moderna Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Moderna, Inc. (0001682852) (Filer)

      5/5/25 4:03:04 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Moderna Inc.

      10-Q - Moderna, Inc. (0001682852) (Filer)

      5/1/25 4:02:14 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Moderna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Moderna, Inc. (0001682852) (Filer)

      5/1/25 6:31:33 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care